Takeda and hutchmed announce marketing authorization application of fruquintinib for previously treated metastatic colorectal cancer validated by the european medicines agency

Osaka, japan & cambridge, mass. & hong kong & shanghai & florham park, n.j.--(business wire)--takeda (tse:4502/nyse:tak) and hutchmed (china) limited (nasdaq/aim: hcm, hkex: 13) (hutchmed) today announced that the european medicines agency (ema) has validated and accepted for regulatory review the marketing authorization application (maa) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (vegfr) -1, -2 and -3 for the treatment of adult pat.
TAK Ratings Summary
TAK Quant Ranking